AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 32 min read$RVTY

Revvity (NYSE:RVTY) surprises with strong Q3 2026, stock soars

Revvity (NYSE:RVTY) reported Q3 2026 revenue of $728.9M, beating estimates by 4.4%, with adjusted EPS of $1.37, a 5.7% beat. The company raised full-year revenue guidance to $2.86B and adjusted EPS guidance to $5.43. Operating and free cash flow margins improved year-over-year.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 11:24 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Revvity (NYSE:RVTY) surprises with strong Q3 2026, stock soars — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$RVTYBullishHigh
01

Why it matters

Beats on revenue and adjusted EPS, plus raised full-year guidance, are typically strong catalysts for re-rating and near-term momentum, especially when accompanied by margin and free cash flow improvement.

02

Market read

Traders can update RVTY expectations immediately based on the beat-and-raise guidance midpoints and improved operating and free cash flow margins.

03

What to watch

Margin and free cash flow improvements are cited, but the article does not break out segment drivers, so traders may discount the durability of the beat if underlying demand trends are unclear.

Relevance 9/10Novelty 9/10Timing: reported Q3 results and same-article full-year guidance raise

Background

The piece is a first report of Revvity’s Q3 2026 results with explicit consensus comparisons and updated full-year guidance.

Company-level read

Ticker impact

$RVTYBullishHigh confidence
Context

Revvity reported Q3 2026 revenue of $728.9M and raised full-year revenue guidance to $2.86B at the midpoint.

Expected impact

Likely upward pressure as the market digests the beat and the slightly higher full-year guidance midpoint.

Evidence & confidence

The article provides multiple company-specific upside datapoints: Q3 revenue and adjusted EPS beats versus consensus, and management raised both full-year revenue and adjusted EPS guidance.

Market effects

Sector

A beat-and-raise in a life sciences tools name can modestly improve sentiment toward the broader research tools and diagnostics supply chain.

Regional

Primarily US large-cap sentiment, with limited direct regional spillover beyond healthcare/life-sciences investors.

Global

Limited global read-through; impact is mostly confined to US-listed healthcare tools positioning.

Counterpoint

What could challenge this read

The guidance increase is described as slight, so the stock may already be priced for upside and could face profit-taking if investors expected a larger raise.

Key entities

  • company
    Revvity

    NYSE-listed life sciences tools company reporting Q3 2026 results and raising full-year guidance.

Read at source← All news

StoryRevvity beats Q3 expectations and raises 2026 guidance

Also covered by

4 outlets

Related articles

NOV 3
$RVTYMed

Revvity, Inc. Q3 2026 Earnings Call Summary

Revvity, Inc. reported Q3 2026 earnings, highlighting a 9% organic growth in Life Sciences, driven by reagent and software demand. Management raised full-year guidance to 5% growth, citing AI-related demand and operational efficiencies. The company expects sustainable margins and plans to divest its China immunodiagnostics business in 2027. Key growth areas include reagents and Signals software, with AI-native offerings launching in 2026.

finance.yahoo.com7 min
NOV 3
$RVTYHighAI 9/10

Revvity Shares Jump Nearly 6% as Q3 Earnings Beat Forecasts and 2026 Guidance Improves

Revvity (RVTY) shares rose 5.55% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.37 vs. $1.30 expected. Revenue grew 4% YoY to $729M, surpassing forecasts. Pro forma revenue, excluding China Immunodiagnostics, increased 7% to $710M. Life Sciences revenue grew 10.8% to $380M, while Diagnostics saw a 2% reported decline but 4% pro forma growth.

finance.yahoo.com5 min
NOV 3
$RVTYHighAI 8/10

Revvity Q3 2026 slides: strong growth, margin expansion lift outlook

Revvity reported Q3 2026 revenue of $710M, up 7% YoY, with adjusted operating margins expanding to 29.4%. EPS grew 21% to $1.37. The company raised full-year guidance, citing strong demand and operational improvements. Life Sciences and Diagnostics segments showed growth, with the Americas and Europe outperforming Asia-Pacific. Revvity's stock surged 8.85% premarket to $165.01.

investing.com2 min
NOV 3
$RVTYHighAI 8/10

Revvity Shares Jump After Strong Q3, Raises Outlook

Revvity shares rose 8.8% premarket after Q3 2026 earnings beat expectations, with adjusted EPS at $1.37 and revenue at $729M. The company raised FY 2026 guidance, targeting $5.40–$5.45 EPS and $2.86B revenue. Life Sciences segment grew 11%, and operating margin improved to 13.1%. CEO attributed results to strong execution. TD Cowen raised its price target to $175 in October.

tradingpedia.com2 min
NOV 3
$RVTYHighAI 8/10

Revvity Announces Financial Results for the Third Quarter of 2026

REVVITY, INC. (RVTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE November 3, 2026 Revvity Announces Financial Results for the Third Quarter of 2026 • Revenue of $729 million; pro forma revenue of $710 million; 7% pro forma revenue growth; 7% pro forma organic revenue growth • GAAP EPS from continuing operations of $0.56 ;

SEC EDGAR 8-K2 min